Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in vitro fertilization with a gonadotropin-releasing hormone antagonist
Authors:
- João Sabino Cunha-FilhoJCJoão Sabino Cunha-Filho
- Nadiane LemosNLNadiane Lemos
- Nina SteinNSNina Stein
- Andréia LaranjeiraALAndréia Laranjeira
- Eduardo Pandolfi PassosEPEduardo Pandolfi Passos
- 30 April 2005
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 83 (4) , 902-907
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Impact of the gonadotropin-releasing hormone antagonist in oocyte donation cyclesFertility and Sterility, 2003
- The use of GnRH antagonists in ovarian stimulationHuman Reproduction Update, 2002
- GnRH antagonist in assisted reproduction: a Cochrane reviewHuman Reproduction, 2002
- Relationship of ovarian stimulation response with vascular endothelial growth factor and degree of granulosa cell apoptosisHuman Reproduction, 2001
- Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulationHuman Reproduction, 2001
- Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trialHuman Reproduction, 2000
- Embryo implantation and GnRH antagonistsHuman Reproduction, 2000
- Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelinHuman Reproduction, 2000
- Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcomeHuman Reproduction, 1999
- A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study groupHuman Reproduction, 1998